Johnson & Johnson (JNJ) EPS (Weighted Average and Diluted) Growth (1y) (2010 - 2026)
Johnson & Johnson (JNJ) EPS (Weighted Average and Diluted) Growth (1y) (2010 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EPS (Weighted Avg. Diluted) Growth (1y) (Qtr) |
| 1 |
Gsk |
92,316,836.42 Bn |
92,316,831.46 Bn |
7.76 Bn |
- |
| 2 |
Eli Lilly |
983.57 Bn |
978.29 Bn |
16.22 Bn |
169.93% |
| 3 |
Johnson & Johnson |
553.56 Bn |
531.50 Bn |
15.96 Bn |
-52.86% |
| 4 |
AbbVie |
383.35 Bn |
374.00 Bn |
10.78 Bn |
-45.83% |
| 5 |
Merck |
281.71 Bn |
276.06 Bn |
12.09 Bn |
-185.57% |
| 6 |
Amgen |
182.20 Bn |
170.16 Bn |
5.87 Bn |
4.37% |
| 7 |
Gilead Sciences |
153.71 Bn |
145.98 Bn |
5.52 Bn |
54.81% |
| 8 |
Pfizer |
143.75 Bn |
130.98 Bn |
-1.21 Bn |
-9.62% |
| 9 |
Bristol Myers Squibb |
109.71 Bn |
99.25 Bn |
8.07 Bn |
9.17% |
| 10 |
Novartis Ag |
108.28 Bn |
107.60 Bn |
- |
- |
| Date | Value |
|---|
| Mar 29, 2026 |
-52.86% |
| Dec 28, 2025 |
48.23% |
| Sep 28, 2025 |
90.99% |
| Jun 29, 2025 |
18.65% |
| Mar 30, 2025 |
238.81% |
| Dec 29, 2024 |
-17.06% |
| Sep 29, 2024 |
-89.13% |
| Jun 30, 2024 |
2,288.47% |
| Mar 31, 2024 |
4,566.67% |
| Dec 31, 2023 |
39.34% |
| Oct 1, 2023 |
507.74% |
| Jul 2, 2023 |
-104.90% |
| Apr 2, 2023 |
-101.55% |
| Oct 2, 2022 |
22.63% |
| Jul 3, 2022 |
-23.40% |
| Apr 3, 2022 |
-16.81% |
| Oct 3, 2021 |
3.01% |
| Jul 4, 2021 |
72.79% |
| Apr 4, 2021 |
6.91% |
| Jan 3, 2021 |
-56.67% |
